Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
Arthroplast Today ; 11: 15-19, 2021 Oct.
Article in English | MEDLINE | ID: mdl-34409142

ABSTRACT

We present a rare case of symptomatic adverse local tissue reaction in a 54-year-old female patient who had undergone total hip arthroplasty with ceramic-on-ceramic bearing. Inflammatory periarticular mass and osteolysis developed in the absence of cobalt chrome alloy interfaces and a modular neck component. On the pathologic images, there was no clear evidence of gross metal staining of tissues, metal corrosion, and ceramic or metal wear particles. However, there were impingement scars on the titanium alloy femoral neck and acetabular cup associated with a high combined anteversion angle of 75° (stem: 40° and cup: 35°), suggesting titanium debris release in vivo. Immunohistochemical staining proved a predominant infiltration of CD4+ T cells and the corresponding IL-17A response to metal. We conclude that neck-rim impingement may lead to the development of adverse local tissue reaction (periarticular mass and osteolysis) due to a metal hypersensitivity with the production of proinflammatory cytokines (IL-17A) by CD4+ T cells even in ceramic-on-ceramic total hip arthroplasty.

2.
Brain Pathol ; 31(5): e12941, 2021 09.
Article in English | MEDLINE | ID: mdl-33624334

ABSTRACT

Alzheimer's disease (AD) is the main cause of dementia, and ß-amyloid (Aß) is a central factor in the initiation and progression of the disease. Different forms of Aß have been identified as monomers, oligomers, and amyloid fibrils. Many proteins have been implicated as putative receptors of respective forms of Aß. Distinct forms of Aß oligomers are considered to be neurotoxic species that trigger the pathophysiology of AD. It was reported that cellular prion protein (PrPC ) is one of the most selective and high-affinity binding partners of Aß oligomers. The interaction of Aß oligomers with PrPC is important to synaptic dysfunction and loss. The binding of Aß oligomers to PrPC has mostly been studied with synthetic peptides, cell culture, and murine models of AD by biochemical and biological methods. However, the molecular mechanisms underlying the relationship between Aß oligomers and PrPC remain unclear, especially in the human brain. We immunohistochemically investigated the relationship between Aß oligomers and PrPC in human brain tissue with and without amyloid pathology. We histologically demonstrate that PrPC accumulates with aging in human brain tissue even prior to AD mainly within diffuse-type amyloid plaques, which are composed of more soluble Aß oligomers without stacked ß-sheet fibril structures. Our results suggest that PrPC accumulating plaques are associated with more soluble Aß oligomers, and appear even prior to AD. The investigation of PrPC accumulating plaques may provide new insights into AD.


Subject(s)
Aging/pathology , Brain/pathology , Plaque, Amyloid/pathology , Prion Proteins/metabolism , Adult , Aged , Aged, 80 and over , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Brain/metabolism , Female , Humans , Male , Middle Aged , Peptide Fragments/metabolism , Plaque, Amyloid/metabolism , PrPC Proteins/metabolism
3.
Am J Surg Pathol ; 45(7): 885-894, 2021 07 01.
Article in English | MEDLINE | ID: mdl-33481388

ABSTRACT

Epithelial-myoepithelial carcinoma (EMC) is a rare salivary gland cancer characterized by biphasic tubular structures composed of inner ductal and outer clear myoepithelial cells. Because of its histologic variety and overlap of histologic features with other salivary gland tumors, there are broad differential diagnoses. The HRAS Q61R mutation has been reported to be frequent in and specific to EMC. We evaluated the usefulness of RAS Q61R mutant-specific immunohistochemical (IHC) staining for detecting this genetic alteration in EMC. We investigated 83 EMC cases and 66 cases of salivary gland tumors with an EMC-like component, including pleomorphic adenoma, adenoid cystic carcinoma, basal cell adenoma/adenocarcinoma, and myoepithelial carcinoma. Sanger sequencing was performed for HRAS, KRAS, and NRAS. The diffuse and membranous/cytoplasmic RAS Q61R IHC expression was observed in 65% of EMC cases, in which all cases harbored the HRAS Q61R mutation. IHC-positive cases were present only in de novo EMCs (54/76 cases, 71%) but not in EMCs ex pleomorphic adenoma. The immunoreactivity was almost always restricted to the myoepithelial cells. Conversely, all EMC cases lacking the HRAS Q61R mutation were negative on IHC. In addition, only 3% of EMC-like tumors showed the abovementioned immunopositivity. None of the cases examined carried KRAS or NRAS mutations. IHC for RAS Q61R is highly sensitive and specific for detecting the HRAS Q61R mutation in EMC. Since significant immunopositivity was almost exclusively identified in nearly two thirds of EMCs but seldom in the histologic mimics, the IHC of RAS Q61R is a useful tool for diagnosing EMC in general pathology laboratories.


Subject(s)
Biomarkers, Tumor/genetics , DNA Mutational Analysis , Immunohistochemistry , Mutation , Myoepithelioma/genetics , Neoplasms, Glandular and Epithelial/genetics , Proto-Oncogene Proteins p21(ras)/genetics , Salivary Gland Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Diagnosis, Differential , Female , Humans , Japan , Male , Middle Aged , Myoepithelioma/pathology , Neoplasms, Glandular and Epithelial/pathology , Predictive Value of Tests , Reproducibility of Results , Retrospective Studies , Salivary Gland Neoplasms/pathology
4.
Acta Biomater ; 99: 284-294, 2019 11.
Article in English | MEDLINE | ID: mdl-31525535

ABSTRACT

Anterior cruciate ligament (ACL) plays an essential role in knee joint stability and kinematics. The microstructural irregularities such as cellular changes and disorganization of the extracellular matrix (ECM) alter the mechanical properties of the ligament, leading to a significant knee functional instability and progression of osteoarthritis (OA). So far, the identification of the local abnormality in ACL has routinely relied on invasive analytical techniques such as histology or biochemical assays. The non-invasive diagnosis using magnetic resonance imaging (MRI) is still limited to identifying the presence/absence of partial/complete ruptures and mucoid degeneration. In this study, laser micro-Raman spectroscopy with near-infrared excitation (785 nm) was applied to human ACL in order to establish optical algorithms for non-destructively diagnosing a degeneration state at molecular level. Raman spectra were obtained from 44 ex-vivo ACL specimens, and these were subsequently classified as an early (subclinical) and advanced (clinical) level of tissue degradation based on the histopathological scoring system. The significant differences in Raman peak intensities were found between the different degeneration groups, which were assigned to the vibrational modes of nucleic acids in cells, collagens, and phospholipids. Linear discriminant analysis (LDA) was performed to identify cut-off values for the distributions of Raman intensity and intensity ratios, which enable to best discriminate between the early and advanced degenerated tissues. Raman intensity algorithms derived from I1101/I1749, [I1002/I1516vs. I1101/I1749], and [I1002/I1749vs. I1101/I1749], yielded a maximum diagnostic sensitivity of 100%, specificity of 80%, and accuracy of 91% for discriminating the degeneration severity. STATEMENT OF SIGNIFICANCE: In this study, laser micro-Raman spectroscopy was applied to human anterior cruciate ligament (ACL) to establish optical algorithms for non-destructively diagnosing the tissue degeneration at molecular level. To our knowledge, this is the first report on Raman diagnosis for human ACL. Linear discriminant analysis (LDA) was performed to identify cut-off values for Raman intensity and intensity ratios, which enable to best discriminate between an early (subclinical) and advanced (clinical) level of ACL degeneration. The intensity ratios of I1101/I1749, [I1002/I1516vs. I1101/I1749], and [I1002/I1749vs. I1101/I1749] yielded a maximum diagnostic sensitivity of 100%, specificity of 80%, and accuracy of 91% for discriminating the ACL degeneration. The present findings might contribute to expanding clinical diagnostic possibilities for non-invasively identifying tissue degeneration.


Subject(s)
Anterior Cruciate Ligament/abnormalities , Knee/anatomy & histology , Spectrum Analysis, Raman/methods , Adolescent , Adult , Aged , Algorithms , Anterior Cruciate Ligament Injuries/physiopathology , Anterior Cruciate Ligament Reconstruction , Arthroplasty, Replacement, Knee , Biomechanical Phenomena , Collagen/metabolism , Diagnosis, Computer-Assisted , Discriminant Analysis , Extracellular Matrix/metabolism , Female , Humans , Knee/physiopathology , Linear Models , Magnetic Resonance Imaging , Male , Middle Aged , Osteoarthritis/physiopathology , Osteoarthritis, Knee/physiopathology , Phospholipids/metabolism , Reproducibility of Results , Sensitivity and Specificity , Spectroscopy, Near-Infrared/methods , Young Adult
5.
J Alzheimers Dis ; 60(2): 511-524, 2017.
Article in English | MEDLINE | ID: mdl-28869466

ABSTRACT

Alzheimer's disease (AD) is increasingly viewed as a disease of synapses. Loss of synapses correlates better with cognitive decline than amyloid plaques and neurofibrillary tangles, the hallmark neuropathological lesions of AD. Soluble forms of amyloid-ß (Aß) have emerged as mediators of synapse dysfunction. Aß binds to, accumulates, and aggregates in synapses. However, the anatomical and neurotransmitter specificity of Aß and the amyloid-ß protein precursor (AßPP) in AD remain poorly understood. In addition, the relative roles of Aß and AßPP in the development of AD, at pre- versus post-synaptic compartments and axons versus dendrites, respectively, remain unclear. Here we use immunogold electron microscopy and confocal microscopy to provide evidence for heterogeneity in the localization of Aß/AßPP. We demonstrate that Aß binds to a subset of synapses in cultured neurons, with preferential binding to glutamatergic compared to GABAergic neurons. We also highlight the challenge of defining pre- versus post-synaptic localization of this binding by confocal microscopy. Further, endogenous Aß42 accumulates in both glutamatergic and GABAergic AßPP/PS1 transgenic primary neurons, but at varying levels. Moreover, upon knock-out of presenilin 1 or inhibition of γ-secretase AßPP C-terminal fragments accumulate both pre- and post-synaptically; however earlier pre-synaptically, consistent with a higher rate of AßPP processing in axons. A better understanding of the synaptic and anatomical selectivity of Aß/AßPP in AD can be important for the development of more effective new therapies for this major disease of aging.


Subject(s)
Amyloid beta-Protein Precursor/metabolism , Gene Expression Regulation, Developmental/genetics , Neurons/cytology , Synapses/metabolism , Amyloid beta-Peptides/pharmacokinetics , Amyloid beta-Protein Precursor/genetics , Animals , Calcium-Calmodulin-Dependent Protein Kinase Type 1/metabolism , Cells, Cultured , Cerebral Cortex/cytology , Diamines/pharmacology , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Developmental/drug effects , Glutamate Decarboxylase/metabolism , Humans , Immunohistochemistry , Mice , Mice, Transgenic , Microtubule-Associated Proteins/metabolism , Mutation/genetics , Neurons/drug effects , Neurons/ultrastructure , Neuropeptides/metabolism , Peptide Fragments/pharmacokinetics , Post-Synaptic Density/drug effects , Post-Synaptic Density/metabolism , Post-Synaptic Density/ultrastructure , Presenilin-1/genetics , Presynaptic Terminals/drug effects , Presynaptic Terminals/metabolism , Presynaptic Terminals/ultrastructure , Protein Binding/drug effects , Protein Binding/genetics , Synapses/drug effects , Synapses/genetics , Synapses/ultrastructure , Synapsins/metabolism , Synaptophysin/metabolism , Thiazoles/pharmacology , Time Factors , tau Proteins/metabolism
6.
Pathol Int ; 67(4): 185-193, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28261941

ABSTRACT

Amyloid plaques and neurofibrillary tangles (NFTs) in the brain are the neuropathological hallmarks of Alzheimer's disease (AD). Amyloid plaques are composed of ß-amyloid peptides (Aß), while NFTs contain hyperphosphorylated tau proteins. Patients with familial AD who have mutations in the amyloid precursor protein (APP) gene have either increased production of Aß or generate more aggregation-prone forms of Aß. The findings of familial AD mutations in the APP gene suggest that Aß plays a central role in the pathophysiology of AD. Aß42, composed of 42 amino acid residues, aggregates readily and is considered to form amyloid plaque. However, the processes of plaque formation are still not well known. It is generally thought that Aß is secreted into the extracellular space and aggregates to form amyloid plaques. Aß as extracellular aggregates and amyloid plaques are thought to be toxic to the surrounding neurons. The intraneuronal accumulation of Aß has more recently been demonstrated and is reported to be involved in synaptic dysfunction, cognitive impairment, and the formation of amyloid plaques in AD. We herein provide an overview of the process of the intraneuronal accumulation of Aß and plaque formation, and discuss its implications for the pathology, early diagnosis, and therapy of AD.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Brain/pathology , Neurons/metabolism , Alzheimer Disease/pathology , Animals , Brain/metabolism , Humans , Neurofibrillary Tangles/metabolism , Neurofibrillary Tangles/pathology
7.
Diagn Cytopathol ; 42(10): 846-55, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24585770

ABSTRACT

Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland neoplasm that is defined by ETV6-NTRK3 gene fusion. There have been few case reports on the cytopathologic features of MASC to date. We examined the clinicopathological and cytological features of seven cases of MASC defined by RT-PCR analysis of the ETV6-NTRK3 fusion gene. The cases occurred in three men and four women aged between 39 and 68 years, with a mean of 51.6 years. In five of these seven cases, the tumor involved the parotid gland. Histologically, all cases displayed predominantly microcystic patterns, often a mixture of follicular and papillary-cystic structures. All tumors were immunoreactive for mammaglobin, S-100 protein, and vimentin. Available fine-needle aspiration cytology smears were cellular and exhibited many loosely cohesive syncytial clusters or isolated cells. Many histiocytes, some of which contained hemosiderin pigments, and variously shaped mucinous material were evident in the background or within the epithelial clusters. The majority of cases showed small to medium-sized follicular structures with secreted materials. Papillary clusters were occasionally found. Tumor cells exhibited small to medium-sized round to oval nuclei, with a smooth contour and indistinct or small nucleoli, and vacuolated cytoplasm. No tumor cells had obvious intracytoplasmic zymogen granules. It appeared that clusters of small to medium-sized follicular and papillary configurations consisting of bland tumor cells with vacuolated cytoplasm, but lack of intracytoplasmic zymogen granules, in a mucinous or hemosiderin-laden histiocyte-rich background, were a characteristic cytological feature highly suggestive of MASC.


Subject(s)
Carcinoma/pathology , Parotid Neoplasms/pathology , Adult , Aged , Biopsy, Fine-Needle , Carcinoma/diagnosis , Carcinoma/metabolism , Female , Humans , Male , Middle Aged , Parotid Neoplasms/diagnosis , Parotid Neoplasms/metabolism , S100 Proteins/genetics , S100 Proteins/metabolism , Secretoglobins/genetics , Secretoglobins/metabolism , Vimentin/genetics , Vimentin/metabolism
8.
PLoS One ; 8(1): e51965, 2013.
Article in English | MEDLINE | ID: mdl-23372648

ABSTRACT

Pathologic aggregation of ß-amyloid (Aß) peptide and the axonal microtubule-associated protein tau protein are hallmarks of Alzheimer's disease (AD). Evidence supports that Aß peptide accumulation precedes microtubule-related pathology, although the link between Aß and tau remains unclear. We previously provided evidence for early co-localization of Aß42 peptides and hyperphosphorylated tau within postsynaptic terminals of CA1 dendrites in the hippocampus of AD transgenic mice. Here, we explore the relation between Aß peptide accumulation and the dendritic, microtubule-associated protein 2 (MAP2) in the well-characterized amyloid precursor protein Swedish mutant transgenic mouse (Tg2576). We provide evidence that localized intraneuronal accumulation of Aß42 peptides is spatially associated with reductions of MAP2 in dendrites and postsynaptic compartments of Tg2576 mice at early ages. Our data support that reduction in MAP2 begins at sites of Aß42 monomer and low molecular weight oligomer (M/LMW) peptide accumulation. Cumulative evidence suggests that accumulation of M/LMW Aß42 peptides occurs early, before high molecular weight oligomerization and plaque formation. Since synaptic alteration is the best pathologic correlate of cognitive dysfunction in AD, the spatial association of M/LMW Aß peptide accumulation with pathology of MAP2 within neuronal processes and synaptic compartments early in the disease process reinforces the importance of intraneuronal Aß accumulation in AD pathogenesis.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , CA1 Region, Hippocampal/metabolism , Microtubule-Associated Proteins/metabolism , Neurites/metabolism , Peptide Fragments/metabolism , Synapses/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/chemistry , Animals , CA1 Region, Hippocampal/pathology , CA1 Region, Hippocampal/physiopathology , Extracellular Space/chemistry , Gene Expression , Humans , Mice , Mice, Transgenic , Microtubule-Associated Proteins/genetics , Neurites/pathology , Peptide Fragments/chemistry , Protein Multimerization , Synapses/pathology , Synaptic Transmission , Time Factors , tau Proteins/genetics , tau Proteins/metabolism
9.
Pathol Res Pract ; 208(12): 736-40, 2012 Dec 15.
Article in English | MEDLINE | ID: mdl-23057997

ABSTRACT

We herein report a case of intrapelvic gastrointestinal stromal tumor (GIST) of undetermined origin in a 48-year-old male who presented with dysuria. An enlarged tumor was detected on digital rectal examination. Imaging studies showed a solid and lobular homogenous tumor of 7.0 cm in diameter. The tumor was attached to the right dorsal aspect of the prostate with compression of the seminal vesicles and rectum. It was considered that the tumor had arisen from the prostate, although the patient's serum prostate-specific antigen level was low (0.436 ng/mL). The histological diagnosis by prostate needle biopsy was a spindle cell tumor. At cystoprostatectomy, the tumor was confirmed to be separated from the prostate by a fibrous band, and showed spindle cells with a fascicular growth pattern, but without necrotic areas. Mitotic figures were noted in 12 of 50 high-power fields. The tumor cells were immunoreactive for the KIT protein (CD117), CD34, Discovered on GIST-1 (DOG-1), and vimentin. In contrast, they were negative for desmin, α-smooth muscle actin, pancytokeratin (AE1/AE3), and S100 protein. The Ki-67 labeling index was 5%. The genetic analyses targeting the c-kit gene revealed a point mutation at codon 559 (GTT→GAT). The diagnosis of GIST was confirmed on the basis of the morphological features, immunoprofile, and results of the molecular analyses. Since extraintestinal GIST can resemble a prostatic tumor clinically, KIT (CD117) and DOG-1 should be considered for inclusion in the immunohistochemical panel for spindle cell tumors obtained by prostate needle biopsy.


Subject(s)
Gastrointestinal Stromal Tumors/diagnosis , Neoplasms, Unknown Primary/diagnosis , Prostate/pathology , Anoctamin-1 , Antigens, CD34/metabolism , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Biopsy, Needle , Chloride Channels/metabolism , DNA Mutational Analysis , DNA, Neoplasm/analysis , Gastrointestinal Stromal Tumors/genetics , Gastrointestinal Stromal Tumors/metabolism , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Neoplasm Proteins/metabolism , Neoplasms, Unknown Primary/genetics , Neoplasms, Unknown Primary/metabolism , Pelvis , Point Mutation , Prostate/metabolism , Prostatectomy , Proto-Oncogene Proteins c-kit/genetics , Treatment Outcome
10.
Neuropathology ; 31(3): 208-14, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21062360

ABSTRACT

Amyloid plaques, a well-known hallmark of Alzheimer's disease (AD), are formed by aggregated ß-amyloid (Aß). The cellular prion protein (PrPc) accumulates concomitantly with Aß in amyloid plaques. One type of amyloid plaque, classified as a neuritic plaque, is composed of an amyloid core and surrounding dystrophic neurites. PrPc immunoreactivity reminiscent of dystrophic neurites is observed in neuritic plaques. Proteinase K treatment prior to immunohistochemistry removes PrPc immunoreactivity from amyloid plaques, whereas Aß immunoreactivity is enhanced by this treatment. In the present study, we used a chemical pretreatment by a sarkosyl solution (0.1% sarkosyl, 75 mM NaOH, 2% NaCl), instead of proteinase K treatment, to evaluate PrPc accumulation within amyloid plaques. Since PrPc within amyloid plaques is removed by this chemical pretreatment, we can recognize that the PrP species deposits within amyloid plaques were PrPc. We could observe that PrPc accumulation in dystrophic neurites occurred differently compared with Aß or hyperphosphorylated tau aggregation in the AD brain. These results could support the hypothesis that PrPc accumulation in dystrophic neurites reflects a response to impairments in cellular degradation, endocytosis, or transport mechanisms associated with AD rather than a non-specific cross-reactivity between PrPc and aggregated Aß or tau.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Neurites/metabolism , Plaque, Amyloid/metabolism , PrPC Proteins/metabolism , Amyloid beta-Peptides/immunology , Amyloid beta-Peptides/metabolism , Blotting, Western , Cross Reactions , Humans , Immunohistochemistry , Neurites/pathology , Plaque, Amyloid/pathology , PrPC Proteins/immunology , tau Proteins/immunology , tau Proteins/metabolism
11.
Acta Neuropathol ; 119(5): 523-41, 2010 May.
Article in English | MEDLINE | ID: mdl-20354705

ABSTRACT

The aberrant accumulation of aggregated beta-amyloid peptides (Abeta) as plaques is a hallmark of Alzheimer's disease (AD) neuropathology and reduction of Abeta has become a leading direction of emerging experimental therapies for the disease. The mechanism(s) whereby Abeta is involved in the pathophysiology of the disease remain(s) poorly understood. Initially fibrils, and subsequently oligomers of extracellular Abeta have been viewed as the most important pathogenic form of Abeta in AD. More recently, the intraneuronal accumulation of Abeta has been described in the brain, although technical considerations and its relevance in AD have made this a controversial topic. Here, we review the emerging evidence linking intraneuronal Abeta accumulation to the development of synaptic pathology and plaques in AD, and discuss the implications of intraneuronal beta-amyloid for AD pathology, biology, diagnosis and therapy.


Subject(s)
Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Neurons/pathology , Synapses/pathology , Alzheimer Disease/metabolism , Brain/metabolism , Brain/pathology , Humans , Neurons/metabolism , Synapses/metabolism , tau Proteins/metabolism
12.
Neurobiol Aging ; 31(7): 1145-52, 2010 Jul.
Article in English | MEDLINE | ID: mdl-18771816

ABSTRACT

Although beta-amyloid (Abeta) plaques and tau neurofibrillary tangles are hallmarks of Alzheimer's disease (AD) neuropathology, loss of synapses is considered the best correlate of cognitive decline in AD, rather than plaques or tangles. How pathological Abeta and tau aggregation relate to each other and to alterations in synapses remains unclear. Since aberrant tau phosphorylation occurs in amyloid precursor protein (APP) Swedish mutant transgenic mice, and since neurofibrillary tangles develop in triple transgenic mice harboring mutations in APP, tau and presenilin 1, we utilized these well-characterized mouse models to explore the relation between Abeta and tau pathologies. We now report that pathological accumulation of Abeta and hyperphosphorylation of tau develop concomitantly within synaptic terminals.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Peptide Fragments/metabolism , Presynaptic Terminals/metabolism , Presynaptic Terminals/pathology , tau Proteins/metabolism , Adult , Alzheimer Disease/diagnosis , Alzheimer Disease/genetics , Amyloid beta-Peptides/genetics , Animals , Disease Models, Animal , Humans , Mice , Mice, Transgenic , Middle Aged , Peptide Fragments/genetics , Phosphorylation/genetics , tau Proteins/genetics
13.
J Biol Chem ; 282(26): 18895-906, 2007 Jun 29.
Article in English | MEDLINE | ID: mdl-17468102

ABSTRACT

Immunotherapy against beta-amyloid peptide (Abeta) is a leading therapeutic direction for Alzheimer disease (AD). Experimental studies in transgenic mouse models of AD have demonstrated that Abeta immunization reduces Abeta plaque pathology and improves cognitive function. However, the biological mechanisms by which Abeta antibodies reduce amyloid accumulation in the brain remain unclear. We provide evidence that treatment of AD mutant neuroblastoma cells or primary neurons with Abeta antibodies decreases levels of intracellular Abeta. Antibody-mediated reduction in cellular Abeta appears to require that the antibody binds to the extracellular Abeta domain of the amyloid precursor protein (APP) and be internalized. In addition, treatment with Abeta antibodies protects against synaptic alterations that occur in APP mutant neurons.


Subject(s)
Alzheimer Disease/therapy , Amyloid beta-Protein Precursor/immunology , Antibodies, Monoclonal/pharmacokinetics , Neurons/pathology , Synapses/pathology , Alzheimer Disease/immunology , Amyloid Precursor Protein Secretases/metabolism , Amyloid beta-Protein Precursor/chemistry , Amyloid beta-Protein Precursor/metabolism , Animals , Antibody Specificity , Antigen-Antibody Complex/metabolism , Cell Line, Tumor , Endocytosis , Immunization/methods , Mice , Mice, Transgenic , Neuroblastoma , Protein Structure, Tertiary , Temperature
14.
J Neurosci ; 26(16): 4277-88, 2006 Apr 19.
Article in English | MEDLINE | ID: mdl-16624948

ABSTRACT

Increasing evidence links intraneuronal beta-amyloid (Abeta42) accumulation with the pathogenesis of Alzheimer's disease (AD). In Abeta precursor protein (APP) mutant transgenic mice and in human AD brain, progressive intraneuronal accumulation of Abeta42 occurs especially in multivesicular bodies (MVBs). We hypothesized that this impairs the MVB sorting pathway. We used the trafficking of the epidermal growth factor receptor (EGFR) and TrkB receptor to investigate the MVB sorting pathway in cultured neurons. We report that, during EGF stimulation, APP mutant neurons demonstrated impaired inactivation, degradation, and ubiquitination of EGFR. EGFR degradation is dependent on translocation from MVB outer to inner membranes, which is regulated by the ubiquitin-proteasome system (UPS). We provide evidence that Abeta accumulation in APP mutant neurons inhibits the activities of the proteasome and deubiquitinating enzymes. These data suggest a mechanism whereby Abeta accumulation in neurons impairs the MVB sorting pathway via the UPS in AD.


Subject(s)
Amyloid beta-Peptides/metabolism , Proteasome Inhibitors , Synaptic Vesicles/metabolism , Ubiquitin/antagonists & inhibitors , Amyloid beta-Peptides/analysis , Amyloid beta-Protein Precursor/analysis , Amyloid beta-Protein Precursor/metabolism , Animals , Cells, Cultured , Epidermal Growth Factor/metabolism , ErbB Receptors/analysis , ErbB Receptors/metabolism , Hippocampus/chemistry , Hippocampus/enzymology , Hippocampus/metabolism , Humans , Male , Mice , Mice, Transgenic , Proteasome Endopeptidase Complex/analysis , Proteasome Endopeptidase Complex/metabolism , Rats , Rats, Sprague-Dawley , Synaptic Vesicles/chemistry , Synaptic Vesicles/enzymology , Ubiquitin/analysis , Ubiquitin/metabolism
15.
Neurobiol Dis ; 20(2): 187-98, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16242627

ABSTRACT

Synaptic dysfunction is increasingly viewed as an early manifestation of Alzheimer's disease (AD), but the cellular mechanism by which beta-amyloid (Abeta) may affect synapses remains unclear. Since cultured neurons derived from APP mutant transgenic mice secrete elevated levels of Abeta and parallel the subcellular Abeta accumulation seen in vivo, we asked whether alterations in synapses occur in this setting. We report that cultured Tg2576 APP mutant neurons have selective alterations in pre- and post-synaptic compartments compared to wild-type neurons. Post-synaptic compartments appear fewer in number and smaller, while active pre-synaptic compartments appear fewer in number and enlarged. Among the earliest changes in synaptic composition in APP mutant neurons were reductions in PSD-95, a protein involved in recruiting and anchoring glutamate receptor subunits to the post-synaptic density. In agreement, we observed early reductions in surface expression of glutamate receptor subunit GluR1 in APP mutant neurons. We provide evidence that Abeta is specifically involved in these alterations in synaptic biology, since alterations in PSD-95 and GluR1 are blocked by gamma-secretase inhibition, and since exogenous addition of synthetic Abeta to wild-type neurons parallels changes in synaptic PSD-95 and GluR1 observed in APP mutant neurons.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/metabolism , Brain/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Membrane Proteins/metabolism , Receptors, AMPA/metabolism , Alzheimer Disease/genetics , Alzheimer Disease/physiopathology , Amyloid Precursor Protein Secretases , Amyloid beta-Peptides/toxicity , Animals , Aspartic Acid Endopeptidases , Brain/pathology , Brain/physiopathology , Cells, Cultured , Dendritic Spines/metabolism , Dendritic Spines/pathology , Disease Models, Animal , Disks Large Homolog 4 Protein , Down-Regulation/physiology , Endopeptidases/drug effects , Endopeptidases/metabolism , Enzyme Inhibitors/pharmacology , Guanylate Kinases , Mice , Mice, Transgenic , Mutation/genetics , Synapses/metabolism , Synapses/pathology , Synaptic Membranes/genetics , Synaptic Membranes/metabolism , Synaptic Membranes/pathology , Synaptic Transmission/genetics
16.
J Neurosci ; 25(29): 6755-64, 2005 Jul 20.
Article in English | MEDLINE | ID: mdl-16033885

ABSTRACT

Accumulation of beta-amyloid (Abeta) peptides in the cerebral cortex is considered a key event in the pathogenesis of Alzheimer's disease (AD). Presenilin 1 (PS1) plays an essential role in the gamma-secretase cleavage of the amyloid precursor protein (APP) and the generation of Abeta peptides. Reduction of Abeta generation via the inhibition of gamma-secretase activity, therefore, has been proposed as a therapeutic approach for AD. In this study, we examined whether genetic inactivation of PS1 in postnatal forebrain-restricted conditional knock-out (PS1 cKO) mice can prevent the accumulation of Abeta peptides and ameliorate cognitive deficits exhibited by an amyloid mouse model that overexpresses human mutant APP. We found that conditional inactivation of PS1 in APP transgenic mice (PS1 cKO;APP Tg) effectively prevented the accumulation of Abeta peptides and formation of amyloid plaques and inflammatory responses, although it also caused an age-related accumulation of C-terminal fragments of APP. Short-term PS1 inactivation in young PS1 cKO;APP Tg mice rescued deficits in contextual fear conditioning and serial spatial reversal learning in a water maze, which were associated with APP Tg mice. Longer-term PS1 inactivation in older PS1 cKO;APP Tg mice, however, failed to rescue the contextual memory and hippocampal synaptic deficits and had a decreasing ameliorative effect on the spatial memory impairment. These results reveal that in vivo reduction of Abeta via the inactivation of PS1 effectively prevents amyloid-associated neuropathological changes and can, but only temporarily, improve cognitive impairments in APP transgenic mice.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/physiopathology , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Membrane Proteins/genetics , Membrane Proteins/metabolism , Aging/pathology , Alzheimer Disease/pathology , Amyloid Precursor Protein Secretases , Amyloidosis/metabolism , Amyloidosis/pathology , Amyloidosis/physiopathology , Animals , Aspartic Acid Endopeptidases , Behavior, Animal/physiology , Endopeptidases/metabolism , Maze Learning/physiology , Memory Disorders/metabolism , Memory Disorders/pathology , Memory Disorders/physiopathology , Memory, Short-Term/physiology , Mice , Mice, Knockout , Mice, Transgenic , Neuronal Plasticity/physiology , Presenilin-1 , Presynaptic Terminals/metabolism , Space Perception/physiology
17.
Neurobiol Aging ; 26(9): 1235-44, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16023263

ABSTRACT

Plaques are a defining neuropathological hallmark of Alzheimer's disease (AD) and the major constituent of plaques, the beta-amyloid peptide (Abeta), is considered to play an important role in the pathophysiology of AD. But the biological origin of Abeta plaques and the mechanism whereby Abeta is involved in pathogenesis have been unknown. Abeta plaques were thought to form from the gradual accumulation and aggregation of secreted Abeta in the extracellular space. More recently, the accumulation of Abeta has been demonstrated to occur within neurons with AD pathogenesis. Moreover, intraneuronal Abeta accumulation has been reported to be critical in the synaptic dysfunction, cognitive dysfunction and the formation of plaques in AD. Here we provide a historical overview on the origin of plaques and a discussion on potential biological and therapeutic implications of intraneuronal Abeta accumulation for AD.


Subject(s)
Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Amyloid beta-Peptides/metabolism , Neurons/metabolism , Plaque, Amyloid/metabolism , Animals , Humans , Models, Biological , Neurofibrillary Tangles/metabolism , Neurofibrillary Tangles/pathology , Neurons/pathology , Neurons/ultrastructure
18.
J Neurochem ; 89(5): 1308-12, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15147524

ABSTRACT

A growing body of evidence suggests a relationship between oxidative stress and beta-amyloid (Abeta) peptide accumulation, a hallmark in the pathogenesis of Alzheimer's disease (AD). However, a direct causal relationship between oxidative stress and Abeta pathology has not been established in vivo. Therefore, we crossed mice with a knockout of one allele of manganese superoxide dismutase (MnSOD), a critical antioxidant enzyme, with Tg19959 mice, which overexpress a doubly mutated human beta-amyloid precursor protein (APP). Partial deficiency of MnSOD, which is well established to cause elevated oxidative stress, significantly increased brain Abeta levels and Abeta plaque burden in Tg19959 mice. These results indicate that oxidative stress can promote the pathogenesis of AD and further support the feasibility of antioxidant approaches for AD therapy.


Subject(s)
Alzheimer Disease/genetics , Amyloid beta-Peptides/metabolism , Amyloid beta-Protein Precursor/genetics , Brain/metabolism , Plaque, Amyloid/genetics , Superoxide Dismutase/deficiency , Amyloid beta-Protein Precursor/biosynthesis , Animals , Brain/pathology , Crosses, Genetic , Disease Models, Animal , Disease Progression , Heterozygote , Humans , Mice , Mice, Inbred C57BL , Mice, Knockout , Mice, Mutant Strains , Oxidative Stress/genetics , Plaque, Amyloid/pathology , Superoxide Dismutase/genetics
19.
J Neurosci ; 24(14): 3592-9, 2004 Apr 07.
Article in English | MEDLINE | ID: mdl-15071107

ABSTRACT

Multiple lines of evidence implicate beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD), but the mechanisms whereby Abeta is involved remain unclear. Addition of Abeta to the extracellular space can be neurotoxic. Intraneuronal Abeta42 accumulation is also associated with neurodegeneration. We reported previously that in Tg2576 amyloid precursor protein mutant transgenic mice, brain Abeta42 localized by immunoelectron microscopy to, and accumulated with aging in, the outer membranes of multivesicular bodies, especially in neuronal processes and synaptic compartments. We now demonstrate that primary neurons from Tg2576 mice recapitulate the in vivo localization and accumulation of Abeta42 with time in culture. Furthermore, we demonstrate that Abeta42 aggregates into oligomers within endosomal vesicles and along microtubules of neuronal processes, both in Tg2576 neurons with time in culture and in Tg2576 and human AD brain. These Abeta42 oligomer accumulations are associated with pathological alterations within processes and synaptic compartments in Tg2576 mouse and human AD brains.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Brain/metabolism , Neurons/metabolism , Peptide Fragments/metabolism , Synapses/metabolism , Adult , Aging/metabolism , Aging/pathology , Alzheimer Disease/pathology , Animals , Brain/pathology , Cells, Cultured , Disease Models, Animal , Endosomes/metabolism , Endosomes/pathology , Fluorescent Antibody Technique , Humans , Macromolecular Substances , Mice , Mice, Transgenic , Microtubules/metabolism , Microtubules/pathology , Middle Aged , Neurons/cytology , Neurons/pathology , Organelles/metabolism , Organelles/pathology , Synapses/pathology
20.
Am J Pathol ; 161(5): 1869-79, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12414533

ABSTRACT

A central question in Alzheimer's disease concerns the mechanism by which beta-amyloid contributes to neuropathology, and in particular whether intracellular versus extracellular beta-amyloid plays a critical role. Alzheimer transgenic mouse studies demonstrate brain dysfunction, as beta-amyloid levels rise, months before the appearance of beta-amyloid plaques. We have now used immunoelectron microscopy to determine the subcellular site of neuronal beta-amyloid in normal and Alzheimer brains, and in brains from Alzheimer transgenic mice. We report that beta-amyloid 42 localized predominantly to multivesicular bodies of neurons in normal mouse, rat, and human brain. In transgenic mice and human Alzheimer brain, intraneuronal beta-amyloid 42 increased with aging and beta-amyloid 42 accumulated in multivesicular bodies within presynaptic and especially postsynaptic compartments. This accumulation was associated with abnormal synaptic morphology, before beta-amyloid plaque pathology, suggesting that intracellular accumulation of beta-amyloid plays a crucial role in Alzheimer's disease.


Subject(s)
Alzheimer Disease/pathology , Amyloid beta-Peptides/analysis , Cytoplasmic Vesicles/chemistry , Neurons/chemistry , Peptide Fragments/analysis , Synapses/ultrastructure , Aging , Alzheimer Disease/metabolism , Amyloid beta-Peptides/immunology , Amyloid beta-Protein Precursor/genetics , Animals , Brain/cytology , Brain/ultrastructure , Cytoplasmic Vesicles/ultrastructure , Humans , Mice , Mice, Knockout , Mice, Transgenic , Microscopy, Immunoelectron , Middle Aged , Neurons/ultrastructure , Peptide Fragments/immunology , Rats , Synapses/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...